Cunningham Bounds Announces Joseph McGowin as Partner

Cunningham Bounds is pleased to announce that Joseph McGowin has been named a Partner of the firm, recognizing his trial skill, leadership, and longstanding commitment to representing individuals and families harmed by negligence and wrongful conduct. Joseph has devoted his career to ensuring that injured clients’ stories are heard–particularly in cases where well-funded defendants seek […]

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of First Citizens BancShares, Inc. – FCNCA

(NASDAQ:FCNCA), NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of First Citizens BancShares, Inc. (“First Citizens” or the “Company”) (NASDAQ: FCNCA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether First Citizens and certain of its officers

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO

(NASDAQ:MREO), NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers and/or directors

/DISREGARD RELEASE: Securus Technologies/

We are advised by Securus Technologies that journalists and other readers should disregard the news release, Securus Technologies Sets the Industry Agenda for Intelligence-Led Corrections at the 2026 ACA Winter Conference, issued 03-Feb-2026 over PR Newswire. SOURCE Securus Technologies https://rt.newswire.ca/rt.gif?NewsItemId=PH77876&Transmission_Id=202602031406PR_NEWS_USPR_____PH77876A&DateId=20260203 COMTEX_472850463/1005/2026-02-03T14:07:06

Briefing: Ensuring children’s access to high quality medical testing

Room 198, Senate Russell Building Laboratory tests are vital to diagnosing and treating children from infancy to adulthood. Join the Association for Diagnostics & Laboratory Medicine (ADLM) and leading experts in laboratory medicine and pediatric health for a timely update on the most pressing challenges facing pediatric testing — and what Congress can do to

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of First Citizens BancShares, Inc. – FCNCA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of First Citizens BancShares, Inc. – FCNCA GlobeNewswire February 03, 2026 NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of First Citizens BancShares, Inc. (“First Citizens” or the “Company”) (NASDAQ: FCNCA). Such investors are advised

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO GlobeNewswire February 03, 2026 NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telesat Corporation – TSAT

(NASDAQ:TSAT), NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Telesat Corporation (“Telesat” or the “Company”) (NASDAQ: TSAT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Telesat and certain of its officers and/or directors have engaged

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. – ORGO

(NASDAQ:ORGO), NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Organogenesis and certain of its officers and/or directors have

Scroll to Top